Benefit from local treatment of the primary tumor in patients with metastatic prostate cancer at diagnosis

Prostate cancer is a frequently diagnosed malignant tumor in older men. The majority is treated with curative intent in a localized stage with either radiotherapy or radical prostatectomy (1). Patients with the diagnosis of metastatic prostate cancer at diagnosis have 5-year survival rates of about 30% (2). Standard first-line treatment is an androgen deprivation therapy (ADT). Initial treatment can also include additional chemotherapy (3).